Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced the appointment of Burt
Adelman, M.D., and Michael D. Kishbauch to the Company’s Board of
Directors, effective April 5, 2016.
Concurrent with the expansion of the Board, Catabasis has formed a
Science and Technology Committee. Dr. Adelman was elected as the Chair
of the Science and Technology Committee and Michael Ross, Ph.D.,
Catabasis Board of Directors Co-Chairman, was appointed as a committee
member. Mr. Kishbauch was appointed to the Audit Committee.
“The appointment of two highly qualified industry experts, Dr. Adelman
and Mr. Kishbauch, to our Board reflects the potential of Catabasis,
including our two Phase 2 clinical stage programs, CAT-1004 and
CAT-2054,” said Jill C. Milne, Ph.D., Chief Executive Officer of
Catabasis. “Both have deep strategic and operational experience
performing senior leadership roles in large-cap pharmaceutical and
development stage biotechnology companies. In particular, Burt brings
extensive drug development and commercialization experience, and Michael
has more than 20 years of executive leadership and company building
experience in the pharmaceutical industry. They will be an integral part
of the team, and we look forward to their contribution and guidance.”
Dr. Adelman most recently served as Executive Vice President, Research
and Development and Chief Medical Officer at Dyax Corp. from February
2012 until its acquisition by Shire Plc in January 2016. Mr. Kishbauch
is currently also a director of Achillion Pharmaceuticals, Inc.,
Progenics Pharmaceuticals, Inc., and Tetralogic Pharmaceuticals
Corporation and previously served as President and Chief Executive
Officer of Achillion from July 2004 until his retirement in September
2013.
“As Chair of the Science and Technology Committee, I’m eager to help
Catabasis continue to advance innovative approaches to treating diseases
with high unmet needs,” said Dr. Adelman.
“I’m looking forward to applying my commercial experience to help propel
Catabasis’ promising pipeline through the clinic for the benefit of
patients seeking to be relieved from the burden of their diseases,” said
Mr. Kishbauch.
About Catabasis
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. We have product candidates in both rare diseases and serious
lipid disorders. Our SMART (Safely Metabolized And Rationally Targeted)
linker drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART linker platform to build an internal pipeline of product
candidates for rare diseases and plan to pursue partnerships to develop
additional product candidates. For more information on the Company's
drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005708/en/
Copyright Business Wire 2016